Abenomics

http://finance.yahoo.com/blogs/the-exchange/road-japanese-debt-crisis-164423450.html?l=1

FNMA 5.15 - No End In Sight

3 Min Chart

 

 

CRM 41.80

JBL 19.70

Don't wanna miss the breakout higher.  Look to buy around 19.75

 

 

 

 

ANF 49.14 -0.88

Closed -0.88, on a day the market was very strong.  DOW was +200 this morning and closed at +106.29.  ANF closed around the 61.8% retracement set from Friday.

 

ENOC 14.50 -3.34

Downgrade, broke thru upward trend.

 

SHLD 49.07

Looking to Short

 

ANF Short $50.70

Target: $45.00

 

 

ANF $50.02

My plan is to take it short starting tomorrow.

 

News Feed

http://seekingalpha.com/currents/all

BBY $26.03

Remember all the chatter was about Best Buy closing down.  Nice bounce.

 

UNXL $24.01

10 Day

 

Cowen & Co.’s Rob Stone this morning reiterates an Outperform rating on shares of touch sensor technology maker Uni-Pixel (UNXL), writing that the 26% plunge in the shares Friday was “significantly overdone,” prompted, he thinks, by a product delay that doesn’t change the company’s fundamental advantages.

 

VVUS $14.82

Is it gonna continue higher?

 

Grove and baker

VVUS

Sold at 13.93, missed the intraday high of 15.36

5 days of green bars leads me to think it'll sell-off a bit then retest highs.

News coming out has been good, break above 15.50 and im buying

Steiner and Hayes

Richmond

FNMA $2.09 - time to short?

VVUS $14.50 Daily Chart

Now if I wasn't already long this position.  Judging by the daily it is a breakout, and in these instances you buy.  Its just hard when you see 15.00 one minute, and 10 minutes later its at 14.50.

 

FEAR AND GREED

FEAR AND GREED

 

VVUS $14.50 - Rallied thru resistance

Looking at the chart yesterday, I was anticipating a big move and luckily it was to the upside.  Why the big movement?  Not really sure, not able to find much news.

 

- First Manhattan Company (FMC) added some heavyweight muscle on Thursday to its bid to shake up the board of drugmaker Vivus Inc(VVUS) by naming former Carl Icahn top lieutenant Alex Denner and two others to its slate of proposed nominees.

Vivus (VVUS) shares rose as much as 11 percent after First Manhattan, which has nearly a 10 percent stake in Vivus(VVUS), expanded its slate of proposed directors from six to nine, including Denner.

Denner, chief investment officer Sarissa Capital Management, has served on boards of biotechnology and other healthcare companies such as Biogen Idec(BIIB) and ImClone Systems, later bought by Eli Lilly and Co. Denner also is a founding partner of Sarissa, which owns about 2 percent of outstanding Vivus(VVUS) shares. Jumping into the Vivus(VVUS) proxy fight is one of his first public forays since starting his own fund.

"In every area that needs to be fixed we want to attract the highest quality human capital," Sam Colin, senior managing director at FMC and a board nominee, said in a telephone interview.

The other two nominees added to the FMC slate are Rolf Bass, who has an extensive European pharmaceutical regulatory background, and Mel Keating, who has expertise in corporate turnarounds.

Asked about the choice of Denner, Colin said, "What we wanted first and foremost was someone with Alex's track record."

"There is no one else like Alex Denner. He's not only incredibly intelligent, incredibly experienced, very thoughtful, he's easy to get along with and very helpful in contentious situations where people's emotions can get the better of them," Colin said.

Denner had been head of healthcare investments for billionaire investor Icahn, and a regular on many of Icahn's proposed director slates.

FMC, in a statement, called its slate of nominees a "clearly superior alternative to Vivus'(VVUS) current board of directors," adding that its nominees offer independence from management.

It has been agitating for change at Vivus(VVUS) since March over the company's disappointing handling of the launch of its diet drug Qsymia, which won U.S. approval in September. Even with Thursday's share gains, Vivus'(VVUS) stock is worth half of what it was last July.

Another top investor, QVT Financial LP, had previously publicly said that Vivus(VVUS) should be sold. Analysts and other investors have been calling on Vivus(VVUS) to find a pharmaceutical company partner with deep pockets and a large sales force to help get Qsymia off the ground.

Vivus (VVUS) reported Qsymia sales of only about $4 million in the first quarter.

"They've got the right asset and the fix is having the right people behind the asset," Colin said of Qsymia. "It should be a huge drug."

Vivus' (VVUS) board of directors is scheduled to be chosen at its annual shareholders meeting on July 15. Its shares closed up 7.2 percent at $14.50 and had climbed as high as $15.04 earlier

 

VVUS $13.52 - Very Important Day Today

If tomorrow VVUS is able to make another green bar, and start tapping the 14's we may see it really bust out.  Lots of resistance around 14, massive congestion area and every time it makes a run for 14 it gets denied.  Considering the way the market reversed today, tomorrow doesn't look promising, but the chart looks like its ready to spring into action.

 

VVUS $12.98

Trying to get over the hump at $13.00.  Had some negative news to the stock last week resulting in the drop.  Is it really bad news?  or just a reason to take profits.

 

VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes

 

Dow Jones 15,335.28

Is the DOW getting top heavy or just gonna keep on grinding higher.  I'm just waiting for a cross-over.

 

Jackson and Taylor

Jackson st

Bush and taylor

Clay and Franklin

Ofarrell and Franklin

California and Lyon

Japantown

Sacramento st

Sai jai at Larkin/ofarrel

One of the better Thai restaurants in the tenderloin

Broderick/lombard

HDGE 16.19

2 Green, 12 Red Bars in last 14 days.

AFFY 1.27

Shares of beaten down biotech concern Affymax(AFFY) have rallied 48%, trading at $1.18, up from near their 52-week bottom of $0.78, apparently related to a SeekingAlpha article published today which cited the company as a good potential turnaround play.

AFFY has a day range of $0.80 - $1.30, with a 52-week top of $27.74.

Price: 1.18, Change: +0.38, Percent Change: +47.50

 

Short Float 42.51%

 

 

1 Month 30 Min

 

 

VVUS 5 Day 30 Min

Vivus(VVUS) is now up 8% at above $13, reversing earlier losses that saw it touch a day low $11.42 after opening at $11.53. It had dropped 3% pre-market. The gains come despite it reporting a wider Q1 loss versus year ago and missing revenue estimates.

The company, in its earnings conference call earlier today, said that it is in talks with larger pharmaceutical companies as part of its efforts to expand commercialization of its weight management drug, Qsymia, according to a report on StreetInsider. VVUS intends to make Qsymia available though retail pharmacies by the middle of July, the report added.

The company earlier reported net loss of $53.6 million or $0.53 per share, as compared to a net loss $18.8 million or $0.20 per share in the comparable quarter a year ago. Analysts, on average, forecast a loss of $0.50 per share on $5.2 million in revenue. It had $4.1 million in Qsymia sales this quarter compared to none a year earlier.

VVUS Short Float 28.74%

 

 

 

10 Day 30 Minutes

 

 

Year To Date

 

 

 

TSLA $56.90

Huge gap up tomorrow after earnings release.

 

 

 

Tesla Motors Inc. (TSLA) said it earned $11.2 million in the first quarter of 2013 as deliveries of Model S electric vehicles lifted the maker of luxury electric cars to a quarterly profit for the first time in its history.

The company--which had reported a loss in every quarter since it public in 2010--said it recognized revenue from 4,900 Model S vehicles in the first quarter, up from the company's previous outlook for 4,500 cars in the quarter.

Shares of Tesla jumped 13.3% after-hours to trade recently at $63.21.

Revenues were $562 million, up from $30.2 million a year ago. Tesla posted a net loss of $89.9 million a year earlier.

The Palo Alto, Calif.-based company is trying to become the first successful automotive startup in the U.S. since the 1920s. As recently as six months ago, the company was forced to sell shares to raise cash and avert a liquidity crisis. Also, Tesla had struggled with delayed deliveries from suppliers that slowed production.

Tesla said its production of Model S vehicles was 400 or more per week, for a total of more than 5,000 vehicles during the first quarter. The company has said it needs to produce at a rate of 20,000 vehicles a year to be profitable.

The company said it is receiving orders for more than 20,000 vehicles a year worldwide, and plans to build about 5,000 Model S vehicles in the second quarter. Tesla plans to deliver about 4,500 vehicles in the second quarter and deliver about 21,000 vehicles during 2013.

"2013 is off to a strong start," Tesla Chairman and Chief Executive Elon Musk and the company's chief financial officer, Deepak Ahuja, wrote in a letter to shareholders.

Tesla launched a new financing program earlier this year that guarantees the value of the Model S after three years, giving buyers the ability to trade in the vehicle to the company at a designated residual value.

The financing options are designed to make the car more affordable to a wider range of buyers, the company added.

Tesla reported first-quarter earnings of $11.2 million, or zero dollars or cents a share, on revenue of $562 million.

Excluding one-time items, adjusted quarterly earnings were $15 million, or 12 cents a share.

Analysts polled by Thomson Reuters were expecting earnings of 4 cents a share on revenue of $500 million.

Gross margin was 17%, up from 8% in the fourth quarter.

P $14.35

Is that an old water reservoir

Union st